INmune Bio to host Feb 26 webinar on new CORDStrom Phase III data for RDEB

Inmune Bio, Inc.

Webinar on February 26, 2026 at 1:00 PM ET to present new MissionEB Phase III data for CORDStrom in RDEB.
Focus: systemic disease-modifying therapy beyond topical care, including EBDASI scores, weight gain, pain/itch reduction, and quality of life.
Featured speakers: Dr. Anna Martinez (Principal Investigator) and CSO Prof. Mark Lowdell.
CORDStrom is a patented allogeneic hucMSC cell medicine positioned for inflammatory/autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.